📣#GICancer highlights from #ASCO26!
Prof. @HPrenen shares his expert insights on key #ColorectalCancer, #PancreaticCancer & #LiverCancer #trialdata from #EMERALD-3, #BREAKWATER & #RASolute 302
How will these data impact clinical practice? Watch his video to find out!
🤝 Programme endorsed by @WarOnCancer
📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #lungcancer, #ProstateCancer & #BreastCancer
⬇️
https://t.co/KHsgeimvv2
This educational programme is supported by COR2ED
#MedEd #HCC #CRCSM #CRC #CancerNurses
1/4 Article of the month: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. @HPrenen
https://t.co/Nmle5tuQYn
Catch the #LowerGI oncology highlights from #ESMO24 📣
👉 https://t.co/ybsrWEpQkT
Profs. @ChiaraCrem1 & @HPrenen explore how new data from a range of trials could impact clinical practice. Don't miss out!
Supported by an independent #MedEd grant from Bayer
@HPrenen#ESMO24 concomitant paper: @DocSacher presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium @HPrenen
🚨 New #LowerGI cancer data from #ESMO24 🚨
Profs. @ChiaraCrem1 & @HPrenen joined us at the congress to each share their insights on new rectal & colorectal cancer data from NICHE-2, NICHE-3 & IMHOTEP trials.
📺Watch their video update
Supported by Bayer #Meded#CRC
📣 New #LowerGI cancer data from #ESMO24 📣
Profs. @ChiaraCrem1 & @HPrenen joined us at the congress to share their insights on new data from POD1UM-303/InterAACT 2, RAMTAS/IKF643 & POCHI trials.
📺Watch their video update
Supported by Bayer #Meded#CRC
📢 #ESMO24 concomitant paper: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. #ESMO24@HPrenen
https://t.co/Nmle5tvoNV
Time to move away from radiotherapy in operable GEA #ESMO24
TOPGEAR ➡️ no survival benefit when RT added to periop chemo
TOPGEAR + ESOPEC : both great trials with a definitive answer = no more RT
✅Great drugs in development - let's focus on systemic Rx for cure @myESMO
Are you excited for #ESMO24 and the emerging data in GI oncology?
Lower GI experts, @ChiaraCrem1 and @HPrenen, will be covering the most hotly anticipated data, including the POD1UM-303 study
Watch this space for more over the coming weeks!
If you are working in the field of GI Cancers and Global Oncology, we invite you to submit to the Article Collection "Treating GI cancers in resource-restricted countries" in Gastrointestinal Oncology: Management and Care. https://t.co/2GLpXXVprr @HPrenen@AORTIC_AFRICA
A panel of GI oncologists discuss the emerging data likely to impact clinical practice
Watch the recorded discussion here 👉https://t.co/TpEZ0F7hTH
Organised in partnership with @eChinaHealth and GI CONNECT members @ModestDominik@HPrenen#MedEd